$SABS
SAB Biotherapeutics, Inc. Stock $sabs

$sabs Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000143774923014634 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$85.52K	$581.1K
YoY Change	-98.65%	-95.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$3.447M
YoY Change	-32.7%	-33.53%
% of Gross Profit
Research & Development	$3.662M	$4.536M
YoY Change	-56.82%	-65.96%
% of Gross Profit
Depreciation & Amortization	$870.0K	$898.0K
YoY Change	16.13%	41.14%
% of Gross Profit
Operating Expenses	$6.562M	$7.983M
YoY Change	-48.82%	-56.87%
Operating Profit	-$6.477M	-$7.402M
YoY Change	-1.01%	10.36%
Interest Expense	$75.32K	$92.39K
YoY Change	-95.3%	28.27%
% of Operating Profit
Other Income/Expense, Net	-$404.3K	$48.19K
YoY Change		-99.38%
Pretax Income	-$6.881M	-$7.354M
YoY Change	41.34%	-782.08%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.881M	-$7.354M
YoY Change	44.07%	-845.93%
Net Earnings / Revenue	-8046.13%	-1265.5%
Basic Earnings Per Share	-$0.14	-$0.15
Diluted Earnings Per Share	-$0.14	-$0.15
COMMON SHARES
Basic Shares Outstanding	50.40M	50.40M
Diluted Shares Outstanding	5.042M	50.40M

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.774M	$13.06M
YoY Change	-53.21%	-41.72%
Cash & Equivalents	$7.774M	$13.06M
Short-Term Investments
Other Short-Term Assets	$867.6K	$1.209M
YoY Change	-42.97%	-38.79%
Inventory
Prepaid Expenses	$867.6K	$1.209M
Receivables	$364.1K	$763.1K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.006M	$15.03M
YoY Change	-67.55%	-58.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.53M	$22.37M
YoY Change	-30.26%	-10.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$434.0K	$434.0K
YoY Change	-18.89%
Total Long-Term Assets	$26.44M	$27.64M
YoY Change	-15.82%	-11.7%
TOTAL ASSETS
Total Short-Term Assets	$9.006M	$15.03M
Total Long-Term Assets	$26.44M	$27.64M
Total Assets	$35.44M	$42.67M
YoY Change	-40.09%	-36.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.404M	$1.445M
YoY Change	-71.6%	-70.99%
Accrued Expenses	$6.453M	$8.654M
YoY Change	-41.31%	-33.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$238.9K	$577.3K
YoY Change	44.12%	237.77%
Total Short-Term Liabilities	$11.01M	$13.67M
YoY Change	-31.77%	-25.14%
LONG-TERM LIABILITIES
Long-Term Debt	$4.027M	$4.138M
YoY Change	9.0%	10.96%
Other Long-Term Liabilities	$687.7K	$466.0K
YoY Change	-68.76%	-88.98%
Total Long-Term Liabilities	$4.715M	$4.604M
YoY Change	-20.04%	-42.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.01M	$13.67M
Total Long-Term Liabilities	$4.715M	$4.604M
Total Liabilities	$15.73M	$18.27M
YoY Change	-28.63%	-30.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.10M	-$55.20M
YoY Change	88.64%	96.14%
Common Stock	$5.286K	$5.094K
YoY Change	21.29%	17.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$5.521M	$5.521M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$19.72M	$24.40M
YoY Change
Total Liabilities & Shareholders Equity	$35.44M	$42.67M
YoY Change	-40.09%	-36.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$6.881M	-$7.354M
YoY Change	44.07%	-845.93%
Depreciation, Depletion And Amortization	$870.0K	$898.0K
YoY Change	16.13%	41.14%
Cash From Operating Activities	-$4.899M	-$1.606M
YoY Change	-5.95%	-84.4%
INVESTING ACTIVITIES
Capital Expenditures	$22.68K	$21.30K
YoY Change	-103.7%	-98.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$22.68K	-$21.30K
YoY Change	-96.3%	-98.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-363.8K	-$359.8K
YoY Change	-1312.23%	-93.53%
NET CHANGE
Cash From Operating Activities	-4.899M	-$1.606M
Cash From Investing Activities	-22.68K	-$21.30K
Cash From Financing Activities	-363.8K	-$359.8K
Net Change In Cash	-5.286M	-$1.987M
YoY Change	-8.74%	-88.41%
FREE CASH FLOW
Cash From Operating Activities	-$4.899M	-$1.606M
Capital Expenditures	$22.68K	$21.30K
Free Cash Flow	-$4.922M	-$1.627M
YoY Change	7.08%	-86.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5556577	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1208781	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1493982	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	15031991	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	22097453	usd
CY2023Q1	sabs	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	434000	usd
CY2022Q4	sabs	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	467694	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	960168	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1192054	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3872157	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3896873	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22373698	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23250853	usd
CY2023Q1	us-gaap	Assets Assets	42672014	usd
CY2022Q4	us-gaap	Assets Assets	50904927	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1444963	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3679116	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	444478	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	772665	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	518012	usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	490000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	490000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50944420
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50944420
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50397762
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50394262
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	546658
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	546658
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY23Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M13D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P15Y7M28D
CY2022Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2022Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03	pure
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39871
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3899721
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 East 54th Street North
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Sioux Falls
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	SD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	57104
CY2023Q1	dei	City Area Code CityAreaCode	605
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	679-6980
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50397762
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13060087	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15046894	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	763123	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	490794	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	132816	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	132788	usd
CY2023Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	2939198	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	0	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8186259	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9917981	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13665726	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14993344	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	227652	usd
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43113353
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	361225	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3596126	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3629642	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	238344	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	320930	usd
CY2023Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	541644	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	541644	usd
CY2023Q1	us-gaap	Liabilities Liabilities	18269492	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19846785	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5094	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5094	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	5521246	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	5521246	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85142249	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84444049	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55223575	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47869755	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	24402522	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31058142	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42672014	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50904927	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	581101	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11803077	usd
CY2023Q1	us-gaap	Revenues Revenues	581101	usd
CY2022Q1	us-gaap	Revenues Revenues	11803077	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4535721	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13324344	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3447389	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5186072	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7983110	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	18510416	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7402009	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6707339	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-82586	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7849572	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	92385	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	72022	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	57988	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	7933	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48189	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7785483	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7353820	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1078144	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92281	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7353820	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	985863	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50397054
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50397054
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1280934	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	328187	usd
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45816651
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38549913	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7830	usd
CY2022Q1	sabs	Shares Issued Value Forward Purchase Agreement Partial Settlement SharesIssuedValueForwardPurchaseAgreementPartialSettlement	817060	usd
CY2022Q1	sabs	Repurchase Of Common Stock Pursuant To Forward Share Purchase Agreement Value RepurchaseOfCommonStockPursuantToForwardSharePurchaseAgreementValue	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	897600	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	985863	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	41258266	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	31058142	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1890	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	93530	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	602780	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7353820	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	24402522	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7353820	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	985863	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	898453	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	636235	usd
CY2023Q1	sabs	Rightofuse Assets Amortization RightofuseAssetsAmortization	24716	usd
CY2022Q1	sabs	Rightofuse Assets Amortization RightofuseAssetsAmortization	41207	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	602780	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	897600	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	14278	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-82586	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7849572	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	93530	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4793454	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3775713	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-318901	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	354612	usd
CY2023Q1	sabs	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-125531	usd
CY2022Q1	sabs	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	18080	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2234157	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	522816	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2022Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-2367	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2939198	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-100000	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	0	usd
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	92281	usd
CY2023Q1	sabs	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	-1731717	usd
CY2022Q1	sabs	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	-599105	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1605717	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9537725	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	76390	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21300	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1357324	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21300	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	755783	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q1	sabs	Payments To Forward Share Purchase Agreement PaymentsToForwardSharePurchaseAgreement	-0	usd
CY2022Q1	sabs	Payments To Forward Share Purchase Agreement PaymentsToForwardSharePurchaseAgreement	5521246	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	33493	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	48751	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1890	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7830	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-359790	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6317950	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1986807	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17136609	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15046894	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39545018	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13060087	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22408409	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	78312	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	72022	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">1</em>) Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> October 22, 2021 (</em>the “Closing Date”), we consummated the business combination contemplated by the agreement and plan of merger, dated as of <em style="font: inherit;"> June 21, 2021, </em>as amended on <em style="font: inherit;"> August 12, 2021, </em>made by and among Big Cypress Acquisition Corp., a Delaware corporation (“BCYP”), Big Cypress Merger Sub Inc., a Delaware corporation (“Merger Sub”), SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or “SAB Biotherapeutics” or the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of the SAB Stockholders (the “Business Combination”). Upon closing of the Business Combination, Merger Sub merged with SAB Biotherapeutics, with SAB Biotherapeutics as the surviving company of the merger. Upon closing of the Business Combination, BCYP changed its name to “SAB Biotherapeutics, Inc.”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SAB is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB’s platform is the <em style="font: inherit;">first</em> to produce fully human antibodies in large animals.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Going Concern </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> March 31, 2023</em>, the Company has experienced net losses, negative cash flows from operations and had an accumulated deficit of $55.2 million. The Company anticipates to continue to generate losses for the foreseeable future and expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, product candidates, and begin commercialization of products. As a result, the Company will require additional capital to fund operations in order to support long-term plans, in particular, following the JPEO Rapid Response Contract Termination. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the <em style="font: inherit;">one</em>-year period following the date that these financial statements were issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through a combination of equity or debt financings, or other <em style="font: inherit;">third</em>-party financing, collaborative or other funding arrangements. Should the Company seek additional financing from outside sources, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to raise such financing on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company <em style="font: inherit;"> may </em>be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The unaudited consolidated financial statements as of <em style="font: inherit;"> March 31, 2023</em>, have been prepared on the basis that the Company will continue as a going concern, and do <em style="font: inherit;">not</em> include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that <em style="font: inherit;"> may </em>result from the possible inability for the Company to continue as a going concern.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55200000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	0.4653	pure
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	401496	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock prior to becoming a public company, determination of the fair value of the Company’s warrants, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized <em style="font: inherit;"> may </em>differ from these estimates.</p>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of credit risk </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, <em style="font: inherit;"> may </em>exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. <span style="background-color:#ffffff;">The Company monitors the financial institutions and the composition of the Company’s accounts. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes that the financial institutions at which the Company’s cash is held are stable. </span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company received 100% of its total revenue through grants from government organizations during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2023 </em>and <em style="font: inherit;">2022</em>.</p>
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19614333
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7353820	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	985863	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50397054
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43113353
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7353820	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	985863	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50397054
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45816651
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50397054
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43113353
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50397054
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45816651
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24369759
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29550674	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29529375	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7176976	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6278522	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22373698	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23250853	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	898000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	636000	usd
CY2023Q1	us-gaap	Acquisition Costs AcquisitionCosts	5000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0618	pure
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0772	pure
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	410588	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	303544	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	368318	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	401496	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	401496	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	401496	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	4382998	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	778906	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6292526	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33242	usd
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2563584	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	745664	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	3728942	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	518012	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	132816	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	227652	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3596126	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	25000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	69000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	72000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	118000	usd
CY2023Q1	sabs	Finance Lease Payments FinanceLeasePayments	103000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	311000	usd
CY2022Q1	sabs	Finance Lease Payments FinanceLeasePayments	121000	usd
CY2023Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	609558	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	511849	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	175736	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	357390	usd
CY2023Q1	sabs	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	0	usd
CY2022Q4	sabs	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	85767	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	509186	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	186833	usd
CY2023Q1	sabs	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	403087	usd
CY2022Q4	sabs	Accrued Clinical Trial Expense AccruedClinicalTrialExpense	355479	usd
CY2023Q1	sabs	Accrued Outside Lab Services AccruedOutsideLabServices	635820	usd
CY2022Q4	sabs	Accrued Outside Lab Services AccruedOutsideLabServices	1106903	usd
CY2023Q1	sabs	Accrued Bonus And Severance AccruedBonusAndSeverance	313602	usd
CY2022Q4	sabs	Accrued Bonus And Severance AccruedBonusAndSeverance	950324	usd
CY2023Q1	sabs	Accrued Contract Manufacturing AccruedContractManufacturing	0	usd
CY2022Q4	sabs	Accrued Contract Manufacturing AccruedContractManufacturing	25129	usd
CY2023Q1	sabs	Accrued Legal Liability AccruedLegalLiability	856505	usd
CY2022Q4	sabs	Accrued Legal Liability AccruedLegalLiability	856505	usd
CY2023Q1	sabs	Accrued Financing Fees Payable AccruedFinancingFeesPayable	4410500	usd
CY2022Q4	sabs	Accrued Financing Fees Payable AccruedFinancingFeesPayable	4910500	usd
CY2023Q1	sabs	Accrued Franchise Tax Payable AccruedFranchiseTaxPayable	50000	usd
CY2022Q4	sabs	Accrued Franchise Tax Payable AccruedFranchiseTaxPayable	50000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	22265	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8192	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	200000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	513110	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	8186259	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9917981	usd
CY2023Q1	sabs	Insurance Policy Premiums Financed Value InsurancePolicyPremiumsFinancedValue	1200000	usd
CY2023Q1	sabs	Insurance Policy Premiums Financed Interest Rate InsurancePolicyPremiumsFinancedInterestRate	0.0547	pure
CY2023Q1	sabs	Insurance Financing Note Payable InsuranceFinancingNotePayable	444000	usd
CY2022Q4	sabs	Insurance Financing Note Payable InsuranceFinancingNotePayable	773000	usd
CY2023Q1	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	500000000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	490000000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12877631
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7095462
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.99
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M14D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	109891	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2546750
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13963
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.59
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3500
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.54
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	28086
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.21
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9596663
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.59
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M19D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4451753
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.92
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y4M20D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4500000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M7D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.39
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.88
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	213000
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	637000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	192000
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	806000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.819	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0376	pure
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	602780	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	897600	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0020	pure
CY2023Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1600000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2023Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03	pure
CY2023Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	76000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	93000	usd

Files In Submission

Name	View Source	Status
sabs-20230331_cal.xml	Edgar Link	unprocessable
sabs-20230331_lab.xml	Edgar Link	unprocessable
0001437749-23-014634-index-headers.html	Edgar Link	pending
0001437749-23-014634-index.html	Edgar Link	pending
0001437749-23-014634.txt	Edgar Link	pending
0001437749-23-014634-xbrl.zip	Edgar Link	pending
ex_505504.htm	Edgar Link	pending
ex_505505.htm	Edgar Link	pending
ex_505506.htm	Edgar Link	pending
ex_505507.htm	Edgar Link	pending
ex_520703.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sabs-20230331.xsd	Edgar Link	pending
sabs20230331_10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sabs-20230331_def.xml	Edgar Link	unprocessable
sabs-20230331_pre.xml	Edgar Link	unprocessable
sabs20230331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SABS
SAB Biotherapeutics, Inc. Stock $sabs

2023 Q2 Form 10-Q Financial Statement

#000143774923014634 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SABS SAB Biotherapeutics, Inc. Stock $sabs

2023 Q2 Form 10-Q Financial Statement

#000143774923014634 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SABS
SAB Biotherapeutics, Inc. Stock $sabs